KDR and neoplasm: The study identified natural compounds (e.g., bergenin and silymarin) that synergize with paclitaxel by inhibiting VEGFR2, significantly enhancing anticancer effects. Experiments confirmed reduced tumor angiogenesis and validated in vivo and in vitro efficacy against metastatic breast cancer